polyarteritis nodosa

GPTKB entity

Statements (56)
Predicate Object
gptkbp:instance_of gptkb:healthcare_organization
gptkbp:bfsLayer 5
gptkbp:bfsParent gptkb:microscopic_polyangiitis
gptkbp:affects medium-sized muscular arteries
gptkbp:associated_with gptkb:hepatitis_B_virus
gptkbp:caused_by immune system dysfunction
gptkbp:clinical_trial treatment efficacy
ongoing studies
new therapies
cardiac involvement
cutaneous manifestations
gastrointestinal involvement
renal involvement
mononeuritis multiplex
gptkbp:code 446.0
M30.0
gptkbp:complications heart problems
kidney damage
nerve damage
skin ulcers
gptkbp:current_use systemic vasculitis
gptkbp:first_described_by in the 19th century
gptkbp:gender more common in males
gptkbp:historical_significance first described by Kussmaul and Maier
important in rheumatology
https://www.w3.org/2000/01/rdf-schema#label polyarteritis nodosa
gptkbp:is_a_route_for inflammation of blood vessels
immune-mediated damage
necrotizing vasculitis
gptkbp:population adults
age range 30-60
more prevalent in certain ethnic groups
gptkbp:premiered_on adulthood
gptkbp:research_focus treatment outcomes
pathogenesis
long-term prognosis
gptkbp:social_responsibility gptkb:granulomatosis_with_polyangiitis
gptkb:Takayasu_arteritis
gptkb:Churg-Strauss_syndrome
gptkb:healthcare_organization
gptkb:rheumatoid_arthritis
biopsy
rare disease
depends on severity
variable outcomes
early treatment improves outcomes
gptkbp:symptoms muscle pain
weight loss
abdominal pain
fever
joint pain
gptkbp:treatment corticosteroids
remission possible
immunosuppressive drugs
long-term follow-up necessary
relapses common